Overview
- RAPIDe-3 met its primary endpoint with a median time to onset of symptom relief of 1.28 hours compared with more than 12 hours on placebo.
- All secondary endpoints were achieved, including End of Progression at 17.47 minutes and complete symptom resolution at 11.95 hours.
- Deucrictibant was well tolerated with no treatment-related serious adverse events and no discontinuations due to side effects.
- The global study enrolled 134 participants across 24 countries and showed consistent efficacy and safety across HAE subtypes and attack severities.
- In treated attacks, 83.0% required a single capsule and 93.2% did not need rescue medication, with an open-label extension study ongoing.